Researchers find new class of highly potent antimalarial compounds

July 10, 2013

Despite renewed global efforts for eradication, malaria continues to exert devastating effects on human health. An estimated 220 million people are infected each year by malaria-causing Plasmodium parasites, which are transmitted by the bite of an infected mosquito. This enormous infection burden leads to some 660,000 lives lost to malaria each year, the majority of these young children in sub-Saharan Africa. While a vaccine to prevent malaria remains elusive, we depend on antimalarial compounds both to treat infections and prevent disease.

Plasmodium parasites progress through two different stages of life in humans and other mammals, the first of which occurs in the liver, and causes no symptoms of disease. The second stage of Plasmodium life occurs in the , and it is here that the parasites can cause severe illness and death. Most current antimalarial compounds target only the malaria parasites growing in the blood, but a great need exists for compounds which could successfully eliminate the parasites in the liver as well, before they begin causing illness.

In work published online today in the journal PNAS, researchers at the Instituto de Medicina Molecular (IMM), in Lisbon, Portugal, have discovered a new class of highly potent antimalarial compounds. These compounds, referred to as Torins, were originally developed by researchers in the Boston, MA to inhibit a key involved in cell growth, mTOR, and have been shown to be effective in rodent models. In research perdormed by Dr. Kirsten Hanson in the laboratory of Dr. Maria Mota, the IMM team and their collaborators have discovered that Torins are extremely effective multistage ; Torins appear to have a novel activity against the Plasmodium parasites themselves, distinct from both currently used malaria therapeutics and from their ability to target human mTOR.

Torins are capable of killing the cultured blood stages of the , Plasmodium falciparum, the species which causes most malaria deaths and severe disease, and are equally potent against the liver stages of a model rodent parasite. A single dose of the compound Torin2 delivered at the beginning of the P. berghei liver stage is sufficient to eliminate infection in mice before any Plasmodium parasites reach the blood. "Given the alarming trend of resistance to our current antimalarial therapies, this is really an exciting finding," says Dr. Mota, the senior author of the study, "and we are already working to develop Torin molecules suitable for clinical trials of antimalarial activity in humans."

Explore further: Cross-species malaria immunity induced by chemically attenuated parasites

More information: Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins, www.pnas.org/cgi/doi/10.1073/pnas.1306097110

Related Stories

New opportunity for rapid treatment of malaria

October 25, 2012

(Medical Xpress)—Researchers have identified a new means to eradicate malaria infections by rapidly killing the blood-borne Plasmodium parasites that cause the disease.

Malaria's severity reset by mosquito

May 30, 2013

(Medical Xpress)—For the first time, researchers have proven that the way in which malaria is transmitted to the host affects how severe the resulting infection will be.

Recommended for you

As cells age, the fat content within them shifts

January 19, 2017

As cells age and stop dividing, their fat content changes, along with the way they produce and break down fat and other molecules classified as lipids, according to a new University at Buffalo study.

What causes sleepiness when sickness strikes

January 19, 2017

It's well known that humans and other animals are fatigued and sleepy when sick, but it's a microscopic roundworm that's providing an explanation of how that occurs, according to a study from researchers at the Perelman School ...

Soft robot helps the heart beat

January 18, 2017

Harvard University and Boston Children's Hospital researchers have developed a customizable soft robot that fits around a heart and helps it beat, potentially opening new treatment options for people suffering from heart ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.